Funding Opportunities Supported by DCTD Programs
| Title | Announcement Number | Expiration Date | Activity Code | Program/Contact |
|---|---|---|---|---|
| Imaging, biomarkers and digital pathomics for the early detection of premetastatic cancer and precancerous lesions associated with lethal phenotypes (Clinical Trial Optional) | PAR-22-131 | September 8, 2025 | R01 | CIP/Huiming Zhang |
| Bioengineering Research Grants (Clinical Trial Optional) | PAR-22-243 | September 8, 2025 | R01 | CDP/Miguel Ossandon |
| Bioengineering Research Grants (Clinical Trial Not Allowed) | PAR-22-242 | September 8, 2025 | R01 | CDP/Miguel Ossandon |
| Coinfection and Cancer (Clinical Trial Not Allowed) | PAR-25-083 | January 8, 2026 | R21 | CIP/Pushpa Tandon |
| Innovative Research in Cancer Nanotechnology (IRCN; Clinical Trial Not Allowed) | PAR-25-106 | May 5, 2026 | R01 | CIP NANO/Piotr Grodzinski and Leela Rani Avula |
| Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (Clinical Trial Not Allowed) | PAR-25-153 | September 8, 2026 | R01 | DTP/Suzanne Forry and Connie Sommers |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 | PAR-23-284 | September 26, 2026 | P50 | TRP Staff |
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (Clinical Trial Not Allowed) | PAR-24-304 | October 15, 2026 | R01 | CDP/Sumana Dey |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (Clinical Trial Not Allowed) | PAR-25-074 | October 15, 2026 | UH2/UH3 | CDP/Sumana Dey, CTEP/Minyung Song |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (Clinical Trial Not Allowed) | PAR-25-075 | October 15, 2026 | UH2/UH3 | CDP/Sumana Dey, CTEP/Minyung Song |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (Clinical Trials Optional) | PAR-25-079 | January 8, 2027 | R01 | CIP/Darrell Tata |
| NCI's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (Clinical Trial Required) | PAR-25-081 | January 8, 2027 | R01 | CTEP/Lori A. Henderson, CIP/Lalitha Shankar, RRP/Jeff Buchsbaum, CDP/Magdalena Thurin, OCCAM/Dan Xi |
| Notice of Special Interest (NOSI): Quantum Sensing Technologies in Biomedical Applications | NOT-EB-23-022 | January 27, 2027 | NOSI | RRP/Jeff Buchsbaum |
| Research Projects to Develop Oncoaging Models for Cancer Research | NOT-CA-23-092 | July 31, 2027 | NOSI | DTP/Weiwei Chen |
| Bioengineering Partnerships with Industry (Clinical Trial Optional) | PAR-24-325 | September 8, 2027 | U01 | CDP/Miguel Ossandon |
| Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (Clinical Trial Optional) | PAR-25-175 | January 8, 2028 | R01 | CIP/Yisong Wang |
| Molecular Imaging of Inflammation in Cancer (Clinical Trial Not Allowed) | PAR-24-311 | January 8, 2028 | R01 | CIP/Charles Lin |